» Articles » PMID: 12604309

Type I Interferon Controls the Onset and Severity of Autoimmune Manifestations in Lpr Mice

Overview
Journal J Autoimmun
Date 2003 Feb 27
PMID 12604309
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Type I Interferons (IFN-I) are immunoregulatory cytokines that enhance activation and survival of many cellular components of the immune system. In the present work, we evaluated the effect of IFN-I on the development of the lymphoproliferative disorder in Fas-defective lpr mice. We report that sustained injection of polyinosinic:polycytidylic acid, a potent inducer of IFN-I, in B6 lpr mice resulted in a dramatic aggravation of the renal disease, higher titers of autoantibodies, a 10-fold increase in serum Ig and accumulation of activated lymphocytes. Moreover, introducing a null mutation for the IFN-I-Receptor gene into the lpr background resulted in dramatic decrease of immune complexes deposition in the kidney and reduced lymphadenopathy. While several recent reports correlated serum levels of IFN-alpha with disease activity in systemic Lupus erythematosus patients, our findings establish a causal link from IFN-I production to the onset and severity of another related autoimmune syndrome.

Citing Articles

Type I Interferons in Systemic Autoimmune Rheumatic Diseases: Pathogenesis, Clinical Features and Treatment Options.

Drougkas K, Skarlis C, Mavragani C Mediterr J Rheumatol. 2024; 35(Suppl 2):365-380.

PMID: 39193187 PMC: 11345602. DOI: 10.31138/mjr.270324.tis.


Targeting mechanistic target of rapamycin complex 2 attenuates immunopathology in Systemic Lupus Erythematosus.

Ai M, Zhou X, Carrer M, Jafar-Nejad P, Li Y, Gades N bioRxiv. 2024; .

PMID: 39131369 PMC: 11312597. DOI: 10.1101/2024.08.01.606069.


EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon α-accelerated murine lupus.

Gallo P, Chain R, Xu J, Whiteman L, Palladino A, Caricchio R Int Immunopharmacol. 2024; 140:112692.

PMID: 39079344 PMC: 11456265. DOI: 10.1016/j.intimp.2024.112692.


Breaking down the cellular responses to type I interferon neurotoxicity in the brain.

Viengkhou B, Hofer M Front Immunol. 2023; 14:1110593.

PMID: 36817430 PMC: 9936317. DOI: 10.3389/fimmu.2023.1110593.


Targeting type I interferons in systemic lupus erythematous.

Bruera S, Chavula T, Madan R, Agarwal S Front Pharmacol. 2023; 13:1046687.

PMID: 36726783 PMC: 9885195. DOI: 10.3389/fphar.2022.1046687.